Johnson & Johnson Acquires Taris Biomedical
December 20 2019 - 4:49PM
Dow Jones News
By Stephen Nakrosis
Johnson & Johnson (JNJ) on Friday said it was acquiring
privately-owned Taris Biomedical LLC, which is developing a "novel
drug delivery technology for the treatment of bladder diseases
including cancer."
Financial terms of the deal weren't disclosed.
JNJ said the proprietary Taris System uses a silicone-based
device to allow for the continuous release of medication into the
bladder.
Taris will become part of Janssen R&D, and will keep a
research presence in the Lexington, Mass. area, JNJ said.
"The team will remain focused on the optimization of drug
candidates working together with Janssen R&D scientists to
advance and deliver future clinical programs applying the Taris
technology," JNJ said.
Mathai Mammen, global head of Janssen R&D, said, "We are
eager to build upon the proof-of-concept data that the Taris team
has generated and advance clinical development of this drug
delivery approach for patients who face a bladder cancer diagnosis,
and potentially for other types of cancer in the future."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 20, 2019 16:34 ET (21:34 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024